Veru (VERU) to Post Earnings on Tuesday

Veru (NASDAQ:VERU) is expected to announce its Q3 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.34) per share and revenue of $1.70 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 8:00 AM ET.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.15. On average, analysts expect Veru to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Veru Price Performance

Veru stock traded up $0.10 during trading hours on Tuesday, reaching $2.35. The stock had a trading volume of 129,790 shares, compared to its average volume of 882,393. The company has a fifty day simple moving average of $2.71 and a 200-day simple moving average of $2.51. Veru has a 52 week low of $2.05 and a 52 week high of $7.33. The stock has a market cap of $37.80 million, a PE ratio of -2.65 and a beta of -1.19.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on VERU shares. Canaccord Genuity Group reiterated a “buy” rating and set a $25.00 target price on shares of Veru in a report on Thursday, June 4th. Wall Street Zen raised Veru to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings cut Veru from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 21st. Finally, Oppenheimer cut their price objective on Veru from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $23.00.

Institutional Investors Weigh In On Veru

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VERU. XTX Topco Ltd bought a new stake in shares of Veru during the 2nd quarter valued at $49,000. Marshall Wace LLP purchased a new stake in Veru in the second quarter worth about $220,000. Qube Research & Technologies Ltd bought a new position in shares of Veru during the second quarter valued at approximately $152,000. Raymond James Financial Inc. increased its stake in shares of Veru by 48.3% during the second quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after purchasing an additional 67,178 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Veru by 5.5% during the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock valued at $108,000 after purchasing an additional 9,637 shares during the last quarter. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.